Jahn Christopher, Juchem Malte, Sonnenschein Kristina, Gietz Anika, Buchegger Theresa, Lachmann Nico, Göhring Gudrun, Behrens Yvonne Lisa, Bär Christian, Thum Thomas, Hoepfner Jeannine
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; Department of Cardiology und Angiology, Hannover Medical School, Hannover, Germany.
Stem Cell Res. 2024 Jun;77:103404. doi: 10.1016/j.scr.2024.103404. Epub 2024 Mar 24.
Fabry disease (FD) is a rare and inherited monogenetic disease caused by mutations in the X-chromosomal alpha-galactosidase A gene GLA concomitant with accumulation of its substrate globotriaosylceramide (Gb3) and multi-organ symptoms. We derived an induced pluripotent stem cell line, MHHi029-A, from a male FD patient carrying a c.959A > T missense mutation in the GLA gene. The hiPSCs show a normal karyotype, expression of pluripotency markers and trilineage differentiation capacity. Importantly, they present the patient-specific mutation in the GLA gene and are therefore a valuable resource for investigating the FD mechanism and identifying novel therapies.
法布里病(FD)是一种罕见的遗传性单基因疾病,由X染色体上的α-半乳糖苷酶A基因(GLA)突变引起,其底物Globotriaosylceramide(Gb3)积累并伴有多器官症状。我们从一名携带GLA基因c.959A>T错义突变的男性FD患者中获得了诱导多能干细胞系MHHi029-A。这些人诱导多能干细胞显示出正常的核型、多能性标志物的表达和三系分化能力。重要的是,它们在GLA基因中存在患者特异性突变,因此是研究法布里病发病机制和鉴定新疗法的宝贵资源。